The results indicated that OCP-PDE2A reduced cAMP concentration in gliomas (Fig. 6I) and that OCP-miR-139 decreased the expression of FZD3 and β-catenin (Fig. 6J). The gene discussed is FZD3; the disease is central nervous system cancer.